A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Healthy

Interventions

DRUG

Pregabalin 150mg

GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)

DRUG

Pregabalin 300mg

GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)